Chimerix Stock Insider Trading
Based on the 100 latest insides trades, we have calculated the insider power to be positive at a ratio of 3.677.
In total, the insiders bought 6 739 793 and sold 6 766 112 CMRX shares in the last 100 trades.
| Date | Action | Amount | Person | Type |
| Jan 26, 2023 | Sell | 3 230 | Jakeman David | Common Stock |
| Jan 17, 2023 | Buy | 192 825 | Andriole Michael T. | Stock Option (Right to Buy) |
| Jan 17, 2023 | Buy | 32 175 | Andriole Michael T. | Common Stock |
| Jan 17, 2023 | Buy | 128 550 | Alrutz Michael Albert | Stock Option (Right to Buy) |
| Jan 17, 2023 | Buy | 21 450 | Alrutz Michael Albert | Common Stock |
| Jan 17, 2023 | Buy | 557 050 | Sherman Michael A. | Stock Option (Right to Buy) |
| Jan 17, 2023 | Buy | 92 950 | Sherman Michael A. | Common Stock |
| Jan 17, 2023 | Buy | 154 260 | Melemed Allen S. | Stock Option (Right to Buy) |
| Jan 17, 2023 | Buy | 25 740 | Melemed Allen S. | Common Stock |
| Jan 17, 2023 | Buy | 24 950 | Jakeman David | Stock Option (Right to Buy) |
| Jan 17, 2023 | Buy | 12 450 | Jakeman David | Common Stock |
| Sep 29, 2022 | Buy | 20 000 | Middleton Fred A | Common Stock |
| Sep 29, 2022 | Sell | 4 400 | Jakeman David | Common Stock |
| Aug 25, 2022 | Sell | 50 000 | Andriole Michael T. | Employee Stock Option (Right to Buy) |
| Aug 25, 2022 | Buy | 50 000 | Andriole Michael T. | Common Stock |
| Jul 25, 2022 | Sell | 100 000 | Sherman Michael A. | Employee Stock Option (Right to Buy) |
| Jul 25, 2022 | Buy | 100 000 | Sherman Michael A. | Common Stock |
| Jun 23, 2022 | Buy | 50 000 | Vakiener Victoria | Stock Option (Right to Buy) |
| Jun 23, 2022 | Buy | 50 000 | Multani Pratik S | Stock Option (Right to Buy) |
| Jun 23, 2022 | Buy | 50 000 | Middleton Fred A | Stock Option (Right to Buy) |
| Jun 23, 2022 | Buy | 50 000 | Machado Patrick | Stock Option (Right to Buy) |
| Jun 23, 2022 | Buy | 50 000 | Meyer Robert J. | Stock Option (Right to Buy) |
| Jun 23, 2022 | Buy | 50 000 | Demski Martha J | Stock Option (Right to Buy) |
| Jun 23, 2022 | Buy | 50 000 | Gilliss Catherine | Stock Option (Right to Buy) |
| May 19, 2022 | Buy | 20 000 | Middleton Fred A | Common Stock |
| May 19, 2022 | Buy | 1 419 | Meyer Robert J. | Common Stock |
| May 19, 2022 | Buy | 9 981 | Meyer Robert J. | Common Stock |
| May 17, 2022 | Buy | 15 000 | Andriole Michael T. | Common Stock |
| May 17, 2022 | Buy | 10 000 | Demski Martha J | Common Stock |
| Feb 04, 2022 | Sell | 3 300 | Jakeman David | Common Stock |
About Chimerix
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midl... CMRX Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
